Lighted antibody imaging in head and neck cancer surgery
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests a special fluorescent dye attached to panitumumab, a cancer-targeting antibody, to help surgeons see tumor tissue more clearly during head and neck cancer surgery. The goal is to improve removal of all cancer cells while sparing healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with head and neck squamous cell carcinoma confirmed by biopsy.
- A doctor has planned surgery that aims to remove all of your cancer.
- You are age 18 or older and in fairly good health (able to do daily activities with little or no help).
- Your heart, liver, kidney, and blood counts are adequate for surgery based on routine tests.
- If you could become pregnant, you agree to use effective birth control or not have sex during the treatment and for 5 months after.
- You have not had an allergic reaction to panitumumab or similar antibody therapies in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special dye attached to the drug nivolumab can help surgeons see cancer cells more clearly during surgery. If you have head and neck cancer and are scheduled for surgery, this study might be an option for you.
This study tests whether two special imaging agents can help doctors see head and neck cancer more clearly during surgery. It may help surgeons remove the cancer more completely while sparing healthy tissue.
This trial tests a new way to give an immunotherapy drug called nivolumab before surgery for head and neck cancer. The drug is injected directly into the tumor and is labeled with a fluorescent marker so researchers can see how it works in the removed tissue. This might help improve treatment for future patients.
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
This Phase 1 study tests a labelling of panitumumab with iodine (111In) to see how well it can identify lymph nodes in head and neck cancer before surgery. The goal is to improve lymph node staging (which can help guide treatment), with the main focus on safety and early performance.
This study tests a special dye (panitumumab-IRDye800) that helps surgeons see brain lesions more clearly during surgery. The dye attaches to a protein on cancer cells and lights up under a special camera, which may help remove more tumor safely.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.